US 12,320,811 B2
Methods of detecting cancer
Anna Daily, Fayetteville, AR (US); and Lindsay Rutherford, Fayetteville, AR (US)
Assigned to Ascendant Diagnostics, LLC, Springdale, AR (US)
Filed by Ascendant Diagnostics, LLC, Springdale, AR (US)
Filed on Apr. 11, 2022, as Appl. No. 17/717,985.
Application 17/717,985 is a continuation of application No. 16/356,879, filed on Mar. 18, 2019, abandoned.
Application 16/356,879 is a continuation of application No. 14/879,982, filed on Oct. 9, 2015, granted, now 10,451,625, issued on Oct. 22, 2019.
Application 14/879,982 is a continuation in part of application No. 14/707,089, filed on May 8, 2015, granted, now 10,613,090, issued on Apr. 7, 2020.
Claims priority of provisional application 62/061,900, filed on Oct. 9, 2014.
Claims priority of provisional application 61/991,061, filed on May 9, 2014.
Prior Publication US 2023/0228753 A1, Jul. 20, 2023
Int. Cl. G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); G01N 30/72 (2006.01); H01J 49/00 (2006.01); H01J 49/40 (2006.01)
CPC G01N 33/57415 (2013.01) [C12Q 1/6886 (2013.01); G01N 30/7233 (2013.01); G01N 33/57488 (2013.01); G01N 33/57496 (2013.01); C12Q 2600/158 (2013.01); H01J 49/00 (2013.01); H01J 49/40 (2013.01)] 16 Claims
 
1. A method of treating breast cancer in a subject, comprising: obtaining a sample of lacrimal secretions from the subject; detecting levels in the sample of at least one marker comprising S100-A11; determining the subject has breast cancer when the levels of S100-A11 are decreased as compared to the levels in a control sample lacking breast cancer; and administering an appropriate anti-cancer therapeutic to the subject when the subject is determined to have breast cancer.